Company Overview

Adaptive Biotechnologies Corporation is a publicly traded biotechnology company that focuses on decoding the adaptive immune system to enable precise diagnostics and therapeutic discovery. The company operates at the intersection of biotechnology, genomics, and immunology, leveraging proprietary immune sequencing and data analytics to profile T-cell and B-cell receptors at scale. Its core value proposition is the ability to translate immune repertoire data into clinically actionable insights.

The company’s primary revenue drivers are immune-based diagnostic tests and research services sold to biopharmaceutical companies, academic institutions, and clinical laboratories. Adaptive Biotechnologies was founded in 2009 and built its early capabilities around high-throughput immune sequencing. Over time, it expanded from research applications into regulated clinical diagnostics, particularly in oncology and immunology, evolving into a platform company with both diagnostics and biopharma partnerships.

Business Operations

Adaptive Biotechnologies operates through two primary business segments: Minimal Residual Disease (MRD) Diagnostics and Immune Medicine. The MRD Diagnostics segment includes the clonoSEQ® test, an FDA-cleared diagnostic used to detect and monitor minimal residual disease in blood cancers such as multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. This segment generates revenue primarily from clinical testing services reimbursed through healthcare systems and research-use testing.

The Immune Medicine segment focuses on providing immune sequencing services and data-driven insights to biopharmaceutical partners engaged in drug discovery and development. The company’s proprietary immunoSEQ® platform and immune database support target discovery, biomarker development, and translational research. Adaptive conducts operations in-house with advanced sequencing laboratories and bioinformatics infrastructure, and it maintains strategic collaborations with pharmaceutical companies rather than relying on joint ventures.

Strategic Position & Investments

Adaptive Biotechnologies’ strategy centers on expanding the clinical adoption of its clonoSEQ® assay while deepening long-term partnerships in immune-driven drug discovery. Growth initiatives include expanding test indications, increasing payer coverage, and integrating immune profiling into standard-of-care decision-making for hematologic malignancies. The company has also invested in scaling automation and data analytics to improve test turnaround time and margin efficiency.

In immune medicine, Adaptive has pursued multi-year collaborations with large pharmaceutical companies to apply its immune mapping technologies to oncology, autoimmune disease, and infectious disease research. Rather than acquiring a large portfolio of subsidiaries, the company has emphasized organic development of its technology platform and monetization through milestone-based and service-based partnerships. Its strategic investments are concentrated in next-generation sequencing, machine learning applied to immune data, and clinical evidence generation.

Geographic Footprint

Adaptive Biotechnologies is headquartered in Seattle, Washington, and operates primarily in North America, where the majority of its clinical testing and revenue generation occurs. The company serves customers across the United States, including hospitals, cancer centers, and biopharmaceutical companies.

Internationally, Adaptive supports research and biopharma customers in Europe and Asia-Pacific, primarily through sample processing, data services, and partnerships rather than extensive physical infrastructure. While global expansion is not driven by large overseas laboratories, the company’s immune sequencing services and diagnostic tests have international reach through collaborations and distributor-supported access.

Leadership & Governance

Adaptive Biotechnologies was co-founded by Harlan Robins and Chad Robins, who were instrumental in establishing the company’s immune sequencing vision and early scientific foundation. The leadership team emphasizes data-driven decision-making, long-term platform development, and the integration of science with clinical utility.

Key executives include:

• Chad Robins – Chief Executive Officer
• Harlan Robins – Co-Founder and Scientific Advisor
• James J. Lally – Chief Operating Officer
• Bridget E. Harnish – Chief Financial Officer
• Dr. Soma Susan Varma – Chief Medical Officer

The leadership philosophy focuses on disciplined execution, regulatory rigor, and leveraging large-scale immune data to create durable competitive advantages in diagnostics and therapeutic discovery.